Effective efgartigimod treatment for severe thymoma‐associated myasthenia gravis experiencing myasthenic crisis: A case report

• DOI: 10.1111/ncn3.12813
• Publication Date: 2024-03-27T06:14:16Z
• Authors: Yukari Morita; Yasushi Osaki; Tomohiro Shogase; Daiji Yoshimoto; Tomomi Terada; Sho Ohtsuru; Kako Yamasaki; Yu Hashimoto; Takuya Matsushita
• Keywords: Thymectomy; Prednisolone; Antibody titer

Abstract We report the long‐term treatment of a 38‐year‐old man with generalized thymoma‐associated myasthenia gravis who was treated efgartigimod. He received chemotherapy and oral prednisolone before thymectomy. However, after initial improvement in symptoms, he deteriorated needed continuous noninvasive positive‐pressure ventilation, highest Myasthenia Gravis‐Activities Daily Living score 14. Immunosuppressive therapy plasma exchange showed limited benefit, anti‐acetylcholine receptor antibody titer peaked to 130 nmol/L. Seven cycles efgartigimod were administered, which improved achieving Gravis‐Actvities 0. The fluctuated until end fifth cycle, thereafter, plateauing at 22 These findings allowed dose be tapered interval between increased.